AU2013334081B2 - Methods for controlling blood pressure and reducing dyspnea in heart failure - Google Patents

Methods for controlling blood pressure and reducing dyspnea in heart failure Download PDF

Info

Publication number
AU2013334081B2
AU2013334081B2 AU2013334081A AU2013334081A AU2013334081B2 AU 2013334081 B2 AU2013334081 B2 AU 2013334081B2 AU 2013334081 A AU2013334081 A AU 2013334081A AU 2013334081 A AU2013334081 A AU 2013334081A AU 2013334081 B2 AU2013334081 B2 AU 2013334081B2
Authority
AU
Australia
Prior art keywords
blood pressure
clevidipine
patient
mmhg
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013334081A
Other languages
English (en)
Other versions
AU2013334081A1 (en
Inventor
Ming-yi HU
Loretta M. Itri
Edward C. Spindler Jr.
Gregory Charles Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of AU2013334081A1 publication Critical patent/AU2013334081A1/en
Assigned to CHIESI FARMACEUTICI S.P.A. reassignment CHIESI FARMACEUTICI S.P.A. Request for Assignment Assignors: THE MEDICINES COMPANY
Application granted granted Critical
Publication of AU2013334081B2 publication Critical patent/AU2013334081B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013334081A 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure Active AU2013334081B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719127P 2012-10-26 2012-10-26
US61/719,127 2012-10-26
PCT/US2013/066990 WO2014066870A1 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Publications (2)

Publication Number Publication Date
AU2013334081A1 AU2013334081A1 (en) 2015-06-11
AU2013334081B2 true AU2013334081B2 (en) 2017-05-18

Family

ID=50545374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013334081A Active AU2013334081B2 (en) 2012-10-26 2013-10-26 Methods for controlling blood pressure and reducing dyspnea in heart failure

Country Status (18)

Country Link
US (1) US10881645B2 (enExample)
EP (1) EP2925128B1 (enExample)
JP (2) JP6329957B2 (enExample)
KR (1) KR102299073B1 (enExample)
CN (2) CN110840890A (enExample)
AU (1) AU2013334081B2 (enExample)
BR (1) BR112015009291B1 (enExample)
CA (1) CA2889584C (enExample)
EA (1) EA030354B1 (enExample)
ES (1) ES2671639T3 (enExample)
IL (1) IL238462A0 (enExample)
MX (1) MX359768B (enExample)
NZ (1) NZ708511A (enExample)
PL (1) PL2925128T3 (enExample)
TR (1) TR201807636T4 (enExample)
UA (1) UA117571C2 (enExample)
WO (1) WO2014066870A1 (enExample)
ZA (1) ZA201503741B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385243B (es) * 2014-05-19 2025-03-14 The Medicines Co Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
CN112118846B (zh) * 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂
CN114966056B (zh) * 2022-06-08 2024-07-02 四川大学华西医院 筛查急性主动脉夹层的试剂盒和系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135617A1 (en) * 2011-04-01 2012-10-04 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9303657D0 (sv) 1993-11-05 1993-11-05 Astra Ab Short-acting dihydropyridines
SE9303744D0 (sv) 1993-11-12 1993-11-12 Astra Ab Pharmaceutical emulsion
SE9804002D0 (sv) 1998-11-23 1998-11-23 Astra Ab New manufacturing process
US8415301B2 (en) 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
CN102186351A (zh) 2008-08-01 2011-09-14 医药公司 药物组合物和用于稳定药物组合物的方法
CA3108961C (en) 2008-08-01 2024-07-02 Hospira, Inc. Pharmaceutical compositions comprising clevidipine and methods for producing low concentrations of impurities thereof
EP2498731B1 (en) * 2009-11-11 2020-01-22 Chiesi Farmaceutici S.p.A. Methods of treating or preventing stent thrombosis
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
WO2012051116A1 (en) * 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012135617A1 (en) * 2011-04-01 2012-10-04 The Medicines Company Short -acting dihydropyridines (clevidipine) for use in reducing stroke damage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ERICKSON, A. L. et al. "Clevidipine: A short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension" Pharmacotherapy (2010) vol. 30, no. 5, pages 515-528 *

Also Published As

Publication number Publication date
CN110840890A (zh) 2020-02-28
NZ708511A (en) 2018-11-30
BR112015009291B1 (pt) 2021-03-16
CA2889584C (en) 2018-08-14
MX359768B (es) 2018-10-10
EA030354B1 (ru) 2018-07-31
KR20150104084A (ko) 2015-09-14
PL2925128T3 (pl) 2018-10-31
EP2925128A1 (en) 2015-10-07
JP2018065875A (ja) 2018-04-26
EA201590825A1 (ru) 2015-09-30
EP2925128A4 (en) 2016-06-08
IL238462A0 (en) 2015-06-30
CN104968199A (zh) 2015-10-07
ZA201503741B (en) 2022-09-28
AU2013334081A1 (en) 2015-06-11
BR112015009291A2 (pt) 2017-07-04
US10881645B2 (en) 2021-01-05
CA2889584A1 (en) 2014-05-01
JP2015535258A (ja) 2015-12-10
KR102299073B1 (ko) 2021-09-09
TR201807636T4 (tr) 2018-06-21
US20140121247A1 (en) 2014-05-01
JP6329957B2 (ja) 2018-05-23
EP2925128B1 (en) 2018-04-11
WO2014066870A1 (en) 2014-05-01
UA117571C2 (uk) 2018-08-27
MX2015005341A (es) 2016-05-24
ES2671639T3 (es) 2018-06-07

Similar Documents

Publication Publication Date Title
EP3607962B1 (en) Angiotensin ii alone or in combination for the treatment of hypotension
JP2026076166A (ja) 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
US10881645B2 (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
Ferguson-Myrthil Novel agents for the treatment of hyponatremia: a review of conivaptan and tolvaptan
EP3074045B1 (en) Sprayable aqueous composition comprising glyceryl trinitrate
US20180140579A1 (en) Sacubitril and valsartan for treating metabolic disease
US20050255096A1 (en) Combination treatment for acute myocardial infarction
RU2623039C2 (ru) Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
KR20200062240A (ko) 시포니모드의 투여 요법
US11911384B2 (en) Vasodilators for treatment of heart failure
CZ300888B6 (cs) Lécivo pro lécení srdecního selhání obsahující antagonistu kortizolu
HK40020897A (en) Methods for controlling blood pressure and reducing dyspnea in heart failure
KR20210032437A (ko) 심부전의 치료를 위한 신규한 약제학적 용도
Oommen et al. Droxidopa for hypotension of different etiologies: two case reports
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
KR20250010046A (ko) IL-6 및/또는 IL-1β 억제제
Khatib Diuretics in heart failure part 2: considerations in practice
Kumar et al. Pharmacological strategies for the treatment of congestive heart failure
Marti et al. Digoxin, Diuretics, and Vasodilators in Patients with Heart Failure
US20070244101A1 (en) Novel compositions and methods of treatment of type ii diabetes and hypertension
Smithburger et al. Antihypertensives and Prostanoids

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CHIESI FARMACEUTICI S.P.A.

Free format text: FORMER APPLICANT(S): THE MEDICINES COMPANY

FGA Letters patent sealed or granted (standard patent)